ProSensa bags GSK deal for RNA-based Duchenne candidates
This article was originally published in Scrip
GlaxoSmithKline has agreed to pay £16 million up front for exclusive global rights to ProSensa's mid-stage RNA-based therapeutic for the genetic disease Duchenne muscular dystrophy (DMD) and options to three further DMD candidates. The deal could be worth up to £428 million to the Dutch biotechnology company if all four products are successfully developed.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.